A multiple-dose study evaluating the pharmacokinetics of 1200 mg once daily and 400 mg twice daily Raltegravir in healthy volunteers

Trial Profile

A multiple-dose study evaluating the pharmacokinetics of 1200 mg once daily and 400 mg twice daily Raltegravir in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 27 May 2017

At a glance

  • Drugs Raltegravir (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 27 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top